All Stories

Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.

Feb 12, 2025 - 14:38
 0
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.
Read More

Tags:

Previous Article

Aluminum tariffs may push Coca-Cola to use more PET packaging

Next Article

Roll out digital € considering peoples’ concerns: EU Parliament to ECB

Related Posts

Roche to house its CVRM research work at Harvard's new research campus

Roche to house its CVRM research work at Harvard's new ...

Mar 7, 2025  0

Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet

Sanofi bounces midstage ILT2 asset back to Biond Biolog...

Mar 3, 2025  0

Fierce Biotech Layoff Tracker 2025: Lyell lets go of 73 workers; Relay sheds staff again

Fierce Biotech Layoff Tracker 2025: Lyell lets go of 73...

Apr 8, 2025  0